Back to news

AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Globe Newswire•16/11/2026•16:15 ET
0

Key Highlights

  • ➤FDA Type 2b feedback supports AEON’s integrated biosimilar development strategy for ABP-450
  • ➤CMAP pharmacodynamic study IND submitted; initiation planned for Q1 2027
  • ➤ABP-450 sequence coverage expanded to approximately 98%, with 100% identity analyzed
  • ➤Approximately $6.2 million in milestone warrant proceeds secured for ABP-450 development
  • ➤Cash and warrant proceeds expected to fund operations into the second quarter of 2027

Expert Statements

Rob Bancroft, President and Chief Executive Officer of AEON Biopharma

“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX(®).”

Rob Bancroft, President and Chief Executive Officer of AEON Biopharma

“Our FDA Type 2b meeting provided valuable direction on integrating comparative analytical and human pharmacodynamic data with an extensive body of existing comparative clinical evidence, while our expanding analytical results continue to strengthen the foundation of our biosimilarity program.”

Rob Bancroft, President and Chief Executive Officer of AEON Biopharma

“Together, these efforts are helping to advance a rigorous, scientifically informed approach to demonstrating biosimilarity to BOTOX(®).”

Rob Bancroft, President and Chief Executive Officer of AEON Biopharma

“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027.”

Rob Bancroft, President and Chief Executive Officer of AEON Biopharma

“We remain focused on building the evidence necessary to bring a biosimilar to BOTOX(®) to the U.S. therapeutic market, representing an opportunity of approximately $3.5 billion annually.”

- Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar development strategy combining comparative analytical assessment, human pharmacodynamic studies, and a substantial body of existing comparative clinical evidence -

- Submitted IND for comparative CMAP pharmacodynamic study, with initiation planned for Q1 2027 -

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in